PL3362480T3 - Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie - Google Patents
Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanieInfo
- Publication number
- PL3362480T3 PL3362480T3 PL16873228T PL16873228T PL3362480T3 PL 3362480 T3 PL3362480 T3 PL 3362480T3 PL 16873228 T PL16873228 T PL 16873228T PL 16873228 T PL16873228 T PL 16873228T PL 3362480 T3 PL3362480 T3 PL 3362480T3
- Authority
- PL
- Poland
- Prior art keywords
- erbb3
- specifically binding
- antibody specifically
- antibody
- binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150173281A KR101746152B1 (ko) | 2015-12-07 | 2015-12-07 | ErbB3에 특이적으로 결합하는 항체 및 그의 용도 |
| EP16873228.7A EP3362480B1 (en) | 2015-12-07 | 2016-11-02 | Antibody specifically binding to erbb3 and use thereof |
| PCT/KR2016/012545 WO2017099362A1 (en) | 2015-12-07 | 2016-11-02 | Antibody specifically binding to erbb3 and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3362480T3 true PL3362480T3 (pl) | 2022-01-03 |
Family
ID=59013461
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16873228T PL3362480T3 (pl) | 2015-12-07 | 2016-11-02 | Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie |
| PL20196712.2T PL3778647T3 (pl) | 2015-12-07 | 2016-11-02 | Przeciwciało specyficznie wiążące się z erbb3 i jego zastosowanie |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20196712.2T PL3778647T3 (pl) | 2015-12-07 | 2016-11-02 | Przeciwciało specyficznie wiążące się z erbb3 i jego zastosowanie |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10413607B2 (pl) |
| EP (2) | EP3362480B1 (pl) |
| JP (2) | JP6982574B2 (pl) |
| KR (1) | KR101746152B1 (pl) |
| CN (2) | CN107683292B (pl) |
| AR (1) | AR107012A1 (pl) |
| AU (1) | AU2016365506B2 (pl) |
| CA (1) | CA3000835C (pl) |
| ES (2) | ES2891990T3 (pl) |
| MX (1) | MX394911B (pl) |
| PL (2) | PL3362480T3 (pl) |
| RU (1) | RU2707121C9 (pl) |
| TW (1) | TWI615406B (pl) |
| WO (1) | WO2017099362A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020080853A1 (ko) * | 2018-10-17 | 2020-04-23 | 주식회사 굳티셀 | Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도 |
| US12551584B1 (en) | 2020-12-07 | 2026-02-17 | Actinium Pharmaceuticals, Inc. | Lewis Y radioimmunotherapy for the treatment of cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0173281B1 (ko) | 1996-11-30 | 1999-02-18 | 양재신 | 자동차의 램프 각도 조절장치 |
| NZ579644A (en) * | 2007-02-16 | 2012-05-25 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| JP5639039B2 (ja) * | 2008-04-11 | 2014-12-10 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| US8895001B2 (en) * | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| KR101764453B1 (ko) * | 2010-04-09 | 2017-08-02 | 아베오 파마슈티컬즈, 인크. | 항-erbb3 항체 |
| ME02637B (me) * | 2010-08-20 | 2017-06-20 | Novartis Ag | Antitela za receptor 3 faktora rasta epiderma (her3) |
| WO2012176779A1 (ja) * | 2011-06-20 | 2012-12-27 | 協和発酵キリン株式会社 | 抗erbB3抗体 |
| WO2013048883A2 (en) | 2011-09-30 | 2013-04-04 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| US11305012B2 (en) * | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
-
2015
- 2015-12-07 KR KR1020150173281A patent/KR101746152B1/ko active Active
-
2016
- 2016-11-02 CN CN201680021403.1A patent/CN107683292B/zh active Active
- 2016-11-02 ES ES16873228T patent/ES2891990T3/es active Active
- 2016-11-02 PL PL16873228T patent/PL3362480T3/pl unknown
- 2016-11-02 PL PL20196712.2T patent/PL3778647T3/pl unknown
- 2016-11-02 US US15/563,227 patent/US10413607B2/en active Active
- 2016-11-02 ES ES20196712T patent/ES3067074T3/es active Active
- 2016-11-02 WO PCT/KR2016/012545 patent/WO2017099362A1/en not_active Ceased
- 2016-11-02 RU RU2018113269A patent/RU2707121C9/ru active
- 2016-11-02 JP JP2018542089A patent/JP6982574B2/ja active Active
- 2016-11-02 CA CA3000835A patent/CA3000835C/en active Active
- 2016-11-02 MX MX2018004228A patent/MX394911B/es unknown
- 2016-11-02 EP EP16873228.7A patent/EP3362480B1/en active Active
- 2016-11-02 EP EP20196712.2A patent/EP3778647B1/en active Active
- 2016-11-02 AU AU2016365506A patent/AU2016365506B2/en active Active
- 2016-11-02 CN CN202011145330.1A patent/CN112472804B/zh active Active
- 2016-12-06 TW TW105140259A patent/TWI615406B/zh active
- 2016-12-07 AR ARP160103758A patent/AR107012A1/es unknown
-
2020
- 2020-03-19 JP JP2020049129A patent/JP6989645B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201903848B (en) | Antibodies that specifically bind to human il-15 and uses thereof | |
| ZA201906813B (en) | Antibody binding specifically to muc1 and use thereof | |
| IL258284A (en) | Anti-Lag 3 antibodies and their uses | |
| IL257263A (en) | Antibodies against angptl8 and their use | |
| IL254517A0 (en) | Antibodies against muc16 and their uses | |
| RS67851B1 (sr) | Proteini koji vezuju anti-tl1a antigen i njihova primena | |
| IL246921A0 (en) | Binding proteins and their uses | |
| ZA201808582B (en) | Antibodies to alpha-synuclein and uses thereof | |
| IL254955A0 (en) | Anti-pacap antibodies and their uses | |
| GB201519858D0 (en) | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof | |
| ZA201708589B (en) | Factor xi antibodies and methods of use | |
| SG11201607109QA (en) | Antibodies that bind egfr and erbb3 | |
| PL2992010T3 (pl) | Modyfikowane asymetryczne przeciwciała wiążące receptor Fc i sposoby ich stosowania | |
| SG11201505762XA (en) | Il-11r binding proteins and uses thereof | |
| IL247315A0 (en) | Anti-acth antibodies and their uses | |
| IL251676A0 (en) | Antibodies that bind to ccr6 and their uses | |
| IL266516B (en) | An antibody that specifically binds to cd66c and its use | |
| GB201503387D0 (en) | Anti-carbapenem antibodies and uses thereof | |
| SG11201704500VA (en) | Antibody binding to neuropilin 1 and use thereof | |
| SG11202001813UA (en) | Polypeptide and antibody bound to polypeptide | |
| PT3233912T (pt) | Antocorpos que se ligam a c6 humano e utilizações destes | |
| PL3660052T3 (pl) | Przeciwciało wiążące się swoiście z białkiem pauf i jego zastosowanie |